CA2224940A1 - Interaction of p53 with transcription factor dp-1 - Google Patents

Interaction of p53 with transcription factor dp-1 Download PDF

Info

Publication number
CA2224940A1
CA2224940A1 CA002224940A CA2224940A CA2224940A1 CA 2224940 A1 CA2224940 A1 CA 2224940A1 CA 002224940 A CA002224940 A CA 002224940A CA 2224940 A CA2224940 A CA 2224940A CA 2224940 A1 CA2224940 A1 CA 2224940A1
Authority
CA
Canada
Prior art keywords
protein
complex
assay
proteins
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002224940A
Other languages
English (en)
French (fr)
Inventor
Nicholas Barrie Lathangue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2224940A1 publication Critical patent/CA2224940A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002224940A 1995-06-30 1996-06-28 Interaction of p53 with transcription factor dp-1 Abandoned CA2224940A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513342.7A GB9513342D0 (en) 1995-06-30 1995-06-30 Complexes
GB9513342.7 1995-06-30

Publications (1)

Publication Number Publication Date
CA2224940A1 true CA2224940A1 (en) 1997-01-23

Family

ID=10776918

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002224940A Abandoned CA2224940A1 (en) 1995-06-30 1996-06-28 Interaction of p53 with transcription factor dp-1

Country Status (6)

Country Link
EP (1) EP0835319A1 (ja)
JP (1) JPH11509089A (ja)
AU (1) AU6237396A (ja)
CA (1) CA2224940A1 (ja)
GB (1) GB9513342D0 (ja)
WO (1) WO1997002354A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610195D0 (en) * 1996-05-15 1996-07-24 Medical Res Council Assay
US6159691A (en) * 1996-05-15 2000-12-12 Prolifix Limited Assay for a putative regulator of cell cycle progression
US6387649B1 (en) 1996-09-30 2002-05-14 Prolifix Limited Assay for a regulator of cell cycle progression
GB9724828D0 (en) * 1997-11-21 1998-01-21 Univ Glasgow Gene
FR2775003A1 (fr) * 1998-02-19 1999-08-20 Transgene Sa Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1
EP1163341A2 (en) * 1999-03-19 2001-12-19 CropDesign N.V. Method for enhancing and/or improving plant growth and/or yield or modifying plant architecture
US8123977B2 (en) 2005-11-07 2012-02-28 Lg Chem, Ltd. Copolymer for liquid crystal alignment, liquid crystal aligning layer including copolymer for liquid crystal alignment, and liquid crystal display including liquid crystal aligning layer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden

Also Published As

Publication number Publication date
GB9513342D0 (en) 1995-09-06
WO1997002354A1 (en) 1997-01-23
AU6237396A (en) 1997-02-05
EP0835319A1 (en) 1998-04-15
JPH11509089A (ja) 1999-08-17

Similar Documents

Publication Publication Date Title
Tassan et al. In vitro assembly of a functional human CDK7‐cyclin H complex requires MAT1, a novel 36 kDa RING finger protein.
Vairo et al. Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members.
Chen et al. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock
Craig et al. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers
Feller et al. c‐Abl kinase regulates the protein binding activity of c‐Crk.
Glenney Jr et al. Amino-terminal sequence of p36 and associated p10: identification of the site of tyrosine phosphorylation and homology with S-100.
Girling et al. A new component of the transcription factor DRTF1/E2F
Kwok et al. Nuclear protein CBP is a coactivator for the transcription factor CREB
Woo et al. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity
Krek et al. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase
Welch et al. Disruption of retinoblastoma protein function by coexpression of its C pocket fragment.
Hayes et al. DDB, a putative DNA repair protein, can function as a transcriptional partner of E2F1
AU728102B2 (en) IGF-1 receptor interacting proteins (IIPs), genes coding therefor and uses thereof
US5582995A (en) Methods of screening for compounds which inhibit the direct binding of Ras to Raf
JP2010063461A (ja) 細胞のＮＦ−κＢ活性化を調節するための組成物および方法
WO1997014794A1 (en) ACTIVATION OF p53 PROTEIN
Cresswell et al. Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2
Götz et al. Protein kinase CK2 interacts with a multi-protein binding domain of p53
AU2001265947B9 (en) Enzymatic assays for screening anti-cancer agents
CA2224940A1 (en) Interaction of p53 with transcription factor dp-1
US6159704A (en) Phosphatase modulator
AU2001265947A1 (en) Enzymatic assays for screening anti-cancer agents
AU2001274026A1 (en) Protein complexes and assays for screening anti-cancer agents
US5871901A (en) Assay for inhibitors of DP-1 and other DP proteins
WO2004012660A2 (en) Mk2 interacting proteins

Legal Events

Date Code Title Description
FZDE Dead